| Trial ID: | L5578 |
| Source ID: | NCT02526615
|
| Associated Drug: |
Rosiglitazone
|
| Title: |
Effects of Rosiglitazone and Metformin on Metabolism in Type 2 Diabetes
|
| Acronym: |
ROSI
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Insulin Sensitivity|Type 2 Diabetes
|
| Interventions: |
DRUG: Rosiglitazone|DRUG: Metformin|DRUG: Placebo
|
| Outcome Measures: |
Primary: insulin sensitivity in skeletal muscle, pre and at 26 weeks measured with euglycemic clamp and 18-F-2-fluoro-2-deoxy-D-glucose scanning skeletal muscle, 26 weeks | Secondary: skeletal muscle blood flow, measured using PET scanning, 26 weeks|insulin signaling pathways in skeletal muscle, measured from muscle biopsies taken before and after intervention, 26 weeks|insulin sensitivity of bone marrow fat, measured using PET images, 26 weeks|insulin stimulated intestinal glucose uptake, measured using PET images, 26 weeks
|
| Sponsor/Collaborators: |
Sponsor: Turku University Hospital | Collaborators: SmithKline Beecham
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
48
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2000-10
|
| Completion Date: |
2001-12
|
| Results First Posted: |
|
| Last Update Posted: |
2015-08-18
|
| Locations: |
Turku PET Centre, Turku, 20520, Finland|Turku university hospital, PET center, Turku, 20520, Finland|Turku PET Centre (Turku University Hospital), Turku, 20521, Finland
|
| URL: |
https://clinicaltrials.gov/show/NCT02526615
|
